Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nevirapine + lamivudine
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a **combination antiretroviral therapy** consisting of the drugs **nevirapine** and **lamivudine**. Nevirapine is classified as a non-nucleoside reverse transcriptase inhibitor (NNRTI), while lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI). This combination is used in the management of **HIV-1 infection** as part of highly active antiretroviral therapy (HAART). Both drugs act by inhibiting the reverse transcriptase enzyme, which is essential for the replication of HIV. The combination can be used with an additional NRTI, such as zidovudine or stavudine, to form a complete regimen. Nevirapine binds directly to reverse transcriptase and blocks the RNA-dependent and DNA-dependent DNA polymerase activities, while lamivudine is incorporated into viral DNA by reverse transcriptase, resulting in chain termination.
- Other names
- nevirapine + lamivudine
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseHIV-2 reverse transcriptaseHBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on nevirapine + lamivudine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nevirapine + lamivudine.